Investor Relations

Eton Pharmaceuticals, Inc. is a commercial company focused on developing, acquiring, and commercializing high-potential therapies for the treatment of patients with rare diseases. We have a diversified pipeline of product candidates across multiple therapeutic areas, and a team with significant expertise in bringing products from clinical trials to patients with exceptional speed.

Volume :

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution
September 13, 2022
-- Expected to be accretive to 2023 earnings -- DEER PARK, Ill. , Sept. 13, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the
Read More
Eton Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
August 30, 2022
DEER PARK, Ill. , Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen , Chief Executive Officer, will
Read More
Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 11, 2022
Total Q2 2022 revenue of $7.4 million , up 139% from prior year Recently launched ALKINDI SPRINKLE ® and Carglumic Acid continue to show robust growth Divestiture of hospital products division to focus on rare disease strategy U.S. Food and Drug Administration (FDA) Approval of Zonisade™
Read More
Email Alerts
Eton Latest Events
More events are coming soon.